Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience.
biomarker testing
lung cancer
older patients
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
received:
29
10
2021
revised:
18
12
2021
accepted:
21
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Genomic and immunologic tumor biomarker testing has dramatically changed the prognosis of patients, particularly those treated for advanced/metastatic non-squamous non-small-cell lung cancer (aNSCLC) when access to targeted agents is available. It remains unclear whether older patients have access to therapy-predictive biomarker testing techniques in the same proportion as younger patients. This study aims to compare the proportion of biomarker testing performed in non-squamous aNSCLC at diagnosis between patients aged ≥70 years old and their younger counterparts. We conducted a retrospective analysis using the Epidemio-Strategy and Medical Economics (ESME) Advanced or Metastatic Lung Cancer Data Platform, a French multicenter real-life database. All patients with non-squamous aNSCLC diagnosed between 2015 and 2018 were selected. Biomarker testing corresponded to at least one molecular alteration and/or PD-L1 testing performed within 1 month before or 3 months after the aNSCLC diagnosis. In total, 2848 patients aged ≥70 years and 6900 patients aged <70 years were included. Most patients were male. The proportion of current smokers at diagnosis was higher in the <70 years group (42% vs. 17%, Age is not a barrier to biomarker testing in patients with aNSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Genomic and immunologic tumor biomarker testing has dramatically changed the prognosis of patients, particularly those treated for advanced/metastatic non-squamous non-small-cell lung cancer (aNSCLC) when access to targeted agents is available. It remains unclear whether older patients have access to therapy-predictive biomarker testing techniques in the same proportion as younger patients. This study aims to compare the proportion of biomarker testing performed in non-squamous aNSCLC at diagnosis between patients aged ≥70 years old and their younger counterparts.
METHODS
METHODS
We conducted a retrospective analysis using the Epidemio-Strategy and Medical Economics (ESME) Advanced or Metastatic Lung Cancer Data Platform, a French multicenter real-life database. All patients with non-squamous aNSCLC diagnosed between 2015 and 2018 were selected. Biomarker testing corresponded to at least one molecular alteration and/or PD-L1 testing performed within 1 month before or 3 months after the aNSCLC diagnosis.
RESULTS
RESULTS
In total, 2848 patients aged ≥70 years and 6900 patients aged <70 years were included. Most patients were male. The proportion of current smokers at diagnosis was higher in the <70 years group (42% vs. 17%,
CONCLUSIONS
CONCLUSIONS
Age is not a barrier to biomarker testing in patients with aNSCLC.
Identifiants
pubmed: 35008257
pii: cancers14010092
doi: 10.3390/cancers14010092
pmc: PMC8750267
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2012 Mar;13(3):300-8
pubmed: 22277837
Lancet Oncol. 2013 Sep;14(10):981-8
pubmed: 23883922
BMC Cancer. 2018 Mar 27;18(1):333
pubmed: 29587656
Respir Investig. 2019 Jan;57(1):40-48
pubmed: 30448243
Cancer Chemother Pharmacol. 2015 Jul;76(1):155-61
pubmed: 26003540
J Clin Oncol. 2009 Mar 20;27(9):1394-400
pubmed: 19224850
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Oncologist. 2019 May;24(5):593-e170
pubmed: 30651400
J Thorac Oncol. 2012 Sep;7(9):1417-22
pubmed: 22895139
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):531-541
pubmed: 31659106
Lancet. 2011 Sep 17;378(9796):1079-88
pubmed: 21831418
Acta Oncol. 2005;44(7):717-22
pubmed: 16227162
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
J Clin Oncol. 2008 May 10;26(14):2350-7
pubmed: 18467727
Lung Cancer. 2018 Dec;126:41-47
pubmed: 30527191
J Thorac Dis. 2019 Nov;11(11):4474-4483
pubmed: 31903235
Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):667-671
pubmed: 30095461
JAMA Oncol. 2020 Jul 1;6(7):e201250
pubmed: 32407455
JAMA. 2019 Aug 27;322(8):764-774
pubmed: 31454018
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
Clin Geriatr Med. 2017 Nov;33(4):563-577
pubmed: 28991651
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2004 Jan 12;90(1):82-6
pubmed: 14710211
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Cancer. 2014 May 15;120(10):1471-81
pubmed: 24700479
J Thorac Oncol. 2020 Sep;15(9):1434-1448
pubmed: 32445813
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Lung Cancer. 2017 May;107:22-35
pubmed: 27316470